Another Cambrex expansion will add 14 jobs

To the Press

Cambrex Corp. recently announced an investment to expand chemical and analytical development capabilities at its Charles City plant that will result in 14 new high-skilled jobs.

The project forms part of the company’s strategic plan to increase its development capacity and resources in North America, according to a news release from the company.

An additional 2,000 square feet of laboratory space will be constructed for development projects, and will support the hiring of an additional 14 chemists. The building, installation and validation of equipment are expected to be completed in the first quarter this year.

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina, where a new 11,000-square-foot analytical laboratory and 400-square-foot pilot plant are currently being completed. These expansions at High Point will create up to 18 new jobs.

“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past five years to meet market demand,” said Joe Nettleton, Charles City site leader and vice president U.S. operations for Cambrex.

“And this, in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” he said. “Our strategy in expanding the development capabilities across the sites at both Charles City and High Point is to ensure both facilities are harmonized and can function synergistically so that projects can be seamlessly transferred between the two.”

Last August, Cambrex announced a $27 million expansion at the Charles City facility that would add 4,500 square feet of production area. Construction and equipment installation was projected to be completed in 2019.

The current $50 million 7,500-square-foot manufacturing facility was opened in 2016.

Cambrex’s Charles City facility is located on a 45-acre site and manufactures a wide range of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, including highly potent molecules and controlled substances.

The High Point site, formerly PharmaCore Inc., was acquired by Cambrex in October 2016, and produces complex APIs and intermediates in batch sizes from milligrams to 100 kilograms to support clinical trials from Phase I to Phase III.

Cambrex Corp. is the leading manufacturer of small molecule innovator and generic APIs. The company offers APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.